**SUPPLEMENTARY MATERIAL**




**Figure S1:** Additional representative analysis of the positive region delimitation. eTreg (1), Foxp3$^{+}$nonTreg (2), naïveTreg (3) and CD4$^{+}$FOXP3$^{-}$CD45RA$^{+}$ T cells (4) (A). Differential PE-conjugated anti-FOXP3 antibody fluorescence intensity in eTreg, Foxp3$^{+}$nonTreg, naiveTreg and CD4$^{+}$FOXP3$^{-}$CD45RA$^{+}$ T cells (4) subtypes (B). FMO control for FOXP3 delimitation (all fluorochromes minus FOXP3 marker) (C).




**Figure S2:** Th17 and Treg related cytokines in the serum of SLE patients and healthy donors (A). Foxp3$^{+}$nonTreg cells related to serum concentrations of IL-17 (B), IL-23 (C), TGF-β (D), IL-10 (E) in SLE patients. All cytokines in SLE patients serum and healthy donors were measured using specific ELISA kits following the manufacturer's recommendations (eBiosciences or BD Biosciences). *$p < 0.05$.



B


CD4+FOXP3+CD25+CD127- % Treg Cells
100
80
60
40
20
0
I.a
I.b
II.a
II.b
III.a
III.b
IV.a
IV.b

C


naïveTreg Cells
30
20
10
0
I.a
I.b
II.a
II.b
III.a
III.b
IV.a
IV.b

D


eTreg Cells
30
20
10
0
I.a
I.b
II.a
II.b
III.a
III.b
IV.a
IV.b

E




**Figure S3:** Treg subsets did not change in relation to the treatment adopted. (%) of the $CD4^{+}FOXP3^{+}$ Treg cells (A), $CD4^{+}FOXP3^{+}CD25^{+}CD127^{-}$ Treg cells (B), naïveTreg cells (C), eTreg cells (D) and $Foxp3^{+}$nonTreg cells in relation to the treatment adopted for SLE patients (E).